CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
119 hedge funds and large institutions have $510M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 19 closing their positions.
147% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 19
108% more call options, than puts
Call options by funds: $6.57M | Put options by funds: $3.15M
81% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 21
53% more capital invested
Capital invested by funds: $334M → $510M (+$176M)
29% more funds holding
Funds holding: 92 → 119 (+27)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$49M |
| 2 |
BlackRock
New York
|
+$21M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$11.5M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$8.96M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5.14M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.45M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$4.03M |
| 4 |
Renaissance Technologies
New York
|
-$3.42M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.56M |
CTIC Hedge Fund Activity: Q2 2022 in Review
119 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2022, worth a combined $510M — up 53% from $334M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CTIC positions and 19 closed out — a net gain of 28 holders — while 38 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $49M. The largest seller was Stonepine Capital Management, cutting an estimated $5.14M.
- 119 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2022, up from 92 in Q1 2022.
- Funds reported $510M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2022, up 53% quarter-over-quarter.
- 47 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2022 and 19 closed out, a net change of +28 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2022 was State Street, an estimated $49M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2022 was Stonepine Capital Management, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2022.